Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
Top Cited Papers
- 7 August 2008
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 359 (6), 584-592
- https://doi.org/10.1056/nejmoa0706130
Abstract
Fibroblast growth factor 23 (FGF-23) is a hormone that increases the rate of urinary excretion of phosphate and inhibits renal production of 1,25-dihydroxyvitamin D, thus helping to mitigate hyperphosphatemia in patients with kidney disease. Hyperphosphatemia and low 1,25-dihydroxyvitamin D levels are associated with mortality among patients with chronic kidney disease, but the effect of the level of FGF-23 on mortality is unknown. We examined mortality according to serum phosphate levels in a prospective cohort of 10,044 patients who were beginning hemodialysis treatment and then analyzed FGF-23 levels and mortality in a nested case–control sample of 200 subjects who died and 200 who survived during the first year of hemodialysis treatment. We hypothesized that increased FGF-23 levels at the initiation of hemodialysis would be associated with increased mortality. Serum phosphate levels in the highest quartile (>5.5 mg per deciliter [1.8 mmol per liter]) were associated with a 20% increase in the multivariable adjusted risk of death, as compared with normal levels (3.5 to 4.5 mg per deciliter [1.1 to 1.4 mmol per liter]) (hazard ratio, 1.2; 95% confidence interval [CI], 1.1 to 1.4). Median C-terminal FGF-23 (cFGF-23) levels were significantly higher in case subjects than in controls (2260 vs. 1406 reference units per milliliter, P<0.001). Multivariable adjusted analyses showed that increasing FGF-23 levels were associated with a monotonically increasing risk of death when examined either on a continuous scale (odds ratio per unit increase in log-transformed cFGF-23 values, 1.8; 95% CI, 1.4 to 2.4) or in quartiles, with quartile 1 as the reference category (odds ratio for quartile 2, 1.6 [95% CI, 0.8 to 3.3]; for quartile 3, 4.5 [95% CI, 2.2 to 9.4]; and for quartile 4, 5.7 [95% CI, 2.6 to 12.6]). Increased FGF-23 levels appear to be independently associated with mortality among patients who are beginning hemodialysis treatment. Future studies might investigate whether FGF-23 is a potential biomarker that can be used to guide strategies for the management of phosphorus balance in patients with chronic kidney disease.Keywords
This publication has 38 references indexed in Scilit:
- Impact of Activated Vitamin D and Race on Survival among Hemodialysis PatientsJournal of the American Society of Nephrology, 2008
- The parathyroid is a target organ for FGF23 in ratsJCI Insight, 2007
- Genetic Ablation of Vitamin D Activation Pathway Reverses Biochemical and Skeletal Anomalies in Fgf-23-Null AnimalsThe American Journal of Pathology, 2006
- Revisiting Survival Differences by Race and Ethnicity among Hemodialysis PatientsJournal of the American Society of Nephrology, 2006
- Regulation of C-Terminal and Intact FGF-23 by Dietary Phosphate in Men and WomenJournal of Bone and Mineral Research, 2006
- Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patientsKidney International, 2006
- Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal studyKidney International, 2006
- Sevelamer Hydrochloride and Calcium Bicarbonate Reduce Serum Fibroblast Growth Factor 23 Levels in Dialysis PatientsTherapeutic Apheresis and Dialysis, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationThe New England Journal of Medicine, 2004
- Disparities in Incidence of Diabetic End-Stage Renal Disease According to Race and Type of DiabetesThe New England Journal of Medicine, 1989